medlogicai.org

Clinical intelligence. Better decisions.

Decision-Making Algorithm in Otorhinolaryngology & Head and Neck Surgery

Allergic Rhinitis

Sneezing, itch and congestion to ARIA-classified, INCS-anchored care — testing, immunotherapy, and the unified airway

Step 1

Step 1 of 14

Presentation & Red-Flag Triage

Rhinitis symptoms + rapid red-flag screen to exclude sinonasal malignancy before allergy workup

Allergic rhinitis presents with sneezing, nasal itch, clear rhinorrhoea, nasal obstruction, postnasal drip, hyposmia, chronic congestion, and sleep disturbance — typically bilateral and symmetrical. Before attributing these to allergy, a rapid red-flag triage excludes sinister sinonasal disease, because the cost of mislabelling a tumour as allergy is high.

Red flagsunilateral nasal obstruction, unilateral blood-stained discharge, persistent epistaxis, facial swelling, proptosis, diplopia, cranial neuropathy, a neck mass, weight loss, a persistent unilateral polyp, or severe facial pain — mandate urgent nasal endoscopy, CT/MRI, and biopsy as indicated to exclude sinonasal malignancy, inverted papilloma, fungal sinusitis, and granulomatous disease (GPA). Their absence allows the structured allergy evaluation to proceed. The discipline here is simple: allergy is bilateral and symmetrical; anything persistently unilateral, bloody, or neurological is not allergic rhinitis until proven otherwise.

  • Symptoms — sneezing, itch, clear rhinorrhoea, obstruction, postnasal drip, hyposmia, congestion, sleep disturbance
  • Red flags — unilateral obstruction/bleeding, epistaxis, facial swelling, proptosis, diplopia, cranial neuropathy, neck mass, weight loss, unilateral polyp, severe pain
  • Red flags → urgent endoscopy + CT/MRI + biopsy (exclude malignancy, inverted papilloma, fungal sinusitis, GPA)
  • Bilateral/symmetrical → proceed to allergy evaluation

★ High-yield pearls (chapter-wide)

  • Unilateral nasal obstruction, blood-stained discharge, a single persistent polyp, facial swelling, proptosis, diplopia, or cranial neuropathy are red flags — endoscope and image before calling it allergy, to exclude sinonasal malignancy, inverted papilloma, fungal sinusitis, and granulomatous disease.
  • Allergic rhinitis is one airway — screen every patient for asthma, conjunctivitis, eczema, chronic rhinosinusitis, nasal polyps, otitis media with effusion, and sleep-disordered breathing, because treating the nose alone misses the disease.
  • ARIA classifies by duration (intermittent vs persistent) and severity (mild vs moderate-severe) — not by season — and that 2×2 drives the choice and intensity of treatment.
  • The intranasal corticosteroid is the single most effective drug for moderate-severe allergic rhinitis and is first-line — more effective than an oral antihistamine for congestion, the symptom patients most want relieved.
  • Spray technique is part of the prescription — head slightly forward, aim the nozzle laterally away from the septum, and breathe gently; forceful sniffing and septal aiming cause epistaxis and failure, not the drug.
  • An intranasal-corticosteroid / intranasal-antihistamine combination beats either agent alone for inadequately controlled disease — escalate to combination before declaring treatment failure.
  • Before escalating, run the failure checklist — right diagnosis, adherence over 80%, correct technique, adequate duration, and environmental control — because most apparent drug failures are one of these.
  • Test (skin-prick or specific IgE) to confirm IgE sensitisation and guide immunotherapy, not to make the diagnosis — a positive test must correlate with the history to be clinically relevant.
  • Allergen immunotherapy (SCIT or SLIT) is the only disease-modifying treatment — it is for confirmed IgE-mediated disease with a relevant allergen, persistent symptoms, or medication failure, and can reduce progression to asthma.
  • A negative allergy test in a symptomatic patient points to non-allergic rhinitis — vasomotor, NARES, drug-induced (including rhinitis medicamentosa), hormonal, or occupational — each with its own management.

Evidence base

4 sources
  1. HIGH

    Seidman MD, Gurgel RK, Lin SY · Otolaryngol Head Neck Surg · 2015Clinical practice guidelinePMID 25644617

    The AAO-HNS allergic-rhinitis guideline — diagnosis, INCS-first pharmacotherapy, testing, and immunotherapy; the spine of this chapter.

  2. HIGH

    Seidman MD, Gurgel RK, Lin SY · Otolaryngol Head Neck Surg · 2015Clinical practice guideline (summary)PMID 25645524

    Executive summary of the AAO-HNS allergic-rhinitis guideline action statements.

  3. HIGH

    Fokkens WJ, Lund VJ, Hopkins C · Rhinology · 2020International position paperPMID 32077450

    EPOS 2020 — the reference standard for chronic rhinosinusitis and CRSwNP diagnosis and management, including biologics and surgery.

  4. HIGH

    Bousquet J, Khaltaev N, Cruz AA · Allergy · 2008International guidelinePMID 18331513

    The ARIA framework — duration/severity classification and the stepwise approach; defines intermittent/persistent and mild/moderate-severe.

Decision tree

The triage screen is the first gate. Classification routes the stable patient to one of the aetiology-keyed pathways below. Cross-cut cards capture the chapter's must-not-miss rules.

Step 1 — TriageRed-flag screenNo red flagPathway classification?Red flags (A)Unilateral/bloody/neurological — endoscopy + imaging + biopsy,exclude malignancyEnvironmental (B)Allergen-specific avoidance bundle for all — mite, pollen,pet, mould, irritantsAntihistamine (C)Mild intermittent — oral 2nd-gen or intranasal antihistamine(weak for congestion)INCS-based (D)Moderate-severe — intranasal corticosteroid first-line;inadequate → INCS+INAHNon-allergic (E)Test-negative — vasomotor, NARES, drug/medicamentosa,hormonal, occupationalTesting (F)Skin-prick (preferred) or specific IgE — correlate positiveswith the historyImmunotherapy (G)SCIT/SLIT — the only disease-modifying option; can reduceprogression to asthmaCRS / polyp (H)Symptoms >12 wks / polyps — endoscopy + CT (EPOS); medicalfirst, then escalateBiologics (I)Severe type-2 CRSwNP — dupilumab (lead), omalizumab,anti-IL-5; or ESSSpecial / maintenance (J)Children/pregnancy/occupational; control → step-down to lowesteffective dosePathways:A Red flagsB EnvironmentalC AntihistamineD INCS-basedE Non-allergicF TestingG ImmunotherapyH CRS / polypI BiologicsJ Special / maintenance
Step 1

Disclaimer

For educational purposes only. Not for clinical use. This platform is an instructional resource intended to support learning about clinical decision-making and the interpretation of investigations. Clinicians remain completely responsible for the interpretation of findings, the formulation of a differential diagnosis, and any clinical decision. Nothing in this application replaces individualized assessment, hands-on training, expert consultation, or established practice guidelines.

Not for profit effort by

Dr. Prahlada N.B

  • MBBS (JJMMC), MS (PGIMER, Chandigarh)
  • MBA in Hospital & Healthcare Management (BITS, Pilani)
  • Postgraduate Certificate in Technology Leadership and Innovation (MIT, USA)
  • Executive Programme in Strategic Management (IIM, Lucknow)
  • Senior Management Programme in Healthcare Management (IIM, Kozhikode)
  • Advanced Certificate in AI for Digital Health and Imaging Program (IISc, Bengaluru)

Supporting organisations

  • Karnataka ENT Hospital and Research Centre (R)
  • Champions Educational and Medical Society (R)
  • Amogh Foundation